Nuvectis Pharma Inc NVCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
-
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
-
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
Trading Information
- Previous Close Price
- $6.37
- Day Range
- $6.06–6.68
- 52-Week Range
- $5.85–12.10
- Bid/Ask
- $6.30 / $6.77
- Market Cap
- $119.00 Mil
- Volume/Avg
- 130,204 / 84,778
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.nuvectis.com
Comparables
Valuation
|
Metric
|
NVCT
|
MGNX
|
CCCC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 9.55 | 3.83 | 1.51 |
Price/Sales | — | 5.57 | 10.98 |
Price/Cash Flow | — | — | — |
Price/Earnings
NVCT
MGNX
CCCC
Financial Strength
|
Metric
|
NVCT
|
MGNX
|
CCCC
|
|---|---|---|---|
Quick Ratio | 3.14 | 2.53 | 4.89 |
Current Ratio | 3.17 | 2.71 | 5.09 |
Interest Coverage | — | −128.87 | −715.67 |
Quick Ratio
NVCT
MGNX
CCCC
Profitability
|
Metric
|
NVCT
|
MGNX
|
CCCC
|
|---|---|---|---|
Return on Assets (Normalized) | −77.54% | −59.21% | −22.53% |
Return on Equity (Normalized) | −106.84% | −120.96% | −34.97% |
Return on Invested Capital (Normalized) | −113.19% | −102.88% | −30.08% |
Return on Assets
NVCT
MGNX
CCCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vttgdkvrs | Nrby | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nvrsqxgd | Brfhbz | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kzrpczp | Flhqyc | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gfwjkwsm | Mxvgwhs | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Hklycyysx | Nlph | $32.8 Bil | |||
| BioNTech SE ADR
BNTX
| Xkpvkgrt | Mmwm | $28.3 Bil | |||
| Moderna Inc
MRNA
| Pymxtwsm | Hxss | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Grvtzdzp | Cln | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nhfmkmzhc | Lbxxcvf | $13.3 Bil | |||
| Incyte Corp
INCY
| Rtyvpvth | Chlsmp | $13.0 Bil |
United States